New data from ESMO 2024 support an initial dose of Radium223 prior to chemotherapy among patients with mCRPC.

“Our findings suggest that high PSMA tumors may respond better to AR-targeting therapies. Tumors with low PSMA possess markers of cancer stem cells and are associated with resistance to radiotherapy," ...

Neal Shore, MD, FACS discusses how a 65-year-old man with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) underwent a treatment journey that included androgen deprivation therapy ...

Panelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while ...

"[Although] we were very excited about the finding in this study showing that Unfold AI could be superior to MRI in detecting extracapsular disease, our next step is to validate this in a ...

“Our findings suggest that high PSMA tumors may respond better to AR-targeting therapies. Tumors with low PSMA possess markers of cancer stem cells and are associated with resistance to radiotherapy," ...

No patients in the transperineal cohort experienced an infection, compared with 1.6% of patients in the transrectal cohort. Transperineal biopsy yielded a lower risk of infectious complications while ...

"My specific career path is really not at all like my mentors, and I think that's fine, actually. It's great, because I'm doing what I want to do and not feeling constrained to go down any particular ...

“What we’ve shown is [EV/pembrolizumab] outperforming chemotherapy in all subgroups," says Thomas B. Powles, MBBS, MRCP, MD. Treatment of locally advanced or metastatic urothelial carcinoma with ...

On Cox regression analysis, glycoproteins were predictive of PFS response to nivolumab plus cabozantinib vs sunitinib (P < .01). Serum glycoproteins involved in complement cascade and lipid metabolism ...

Michael Gorin, MD provides the background and results of two key imaging trials that reviewed the efficacy of this new copper-based agent.

According to the authors, data from the CONTACT-02 trial show that cabozantinib plus atezolizumab may benefit selected patients with mCRPC. Data from the final overall survival (OS) analysis from the ...